About GSK plc
https://www.gsk.comGSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
CEO
Julie Belita Brown
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-07-22 | Forward | 613:500 |
| 2022-07-19 | Reverse | 4:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 82
Ratings Snapshot
Rating : B+
Price Target
Institutional Ownership
DODGE & COX
Shares:78.4M
Value:$3.98B
FMR LLC
Shares:66.14M
Value:$3.36B
FISHER ASSET MANAGEMENT, LLC
Shares:32.23M
Value:$1.64B
Summary
Showing Top 3 of 1,271
About GSK plc
https://www.gsk.comGSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $8.55B ▲ | $3.7B ▼ | $2.01B ▲ | 23.55% ▲ | $5.72 ▲ | $3.36B ▲ |
| Q2-2025 | $7.99B ▲ | $3.8B ▲ | $1.44B ▼ | 18.07% ▼ | $0.72 ▼ | $3.23B ▲ |
| Q1-2025 | $7.52B ▼ | $3.36B ▼ | $1.62B ▲ | 21.61% ▲ | $0.8 ▲ | $3.09B ▲ |
| Q4-2024 | $8.12B ▲ | $4.86B ▼ | $414M ▲ | 5.1% ▲ | $0.2 ▲ | $1.12B ▼ |
| Q3-2024 | $8.01B | $5.43B | $-58M | -0.72% | $-0.03 | $1.17B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $4.45B ▼ | $82.58B ▲ | $61.37B ▼ | $21.74B ▲ |
| Q2-2025 | $4.96B ▼ | $81.2B ▲ | $61.53B ▲ | $20.27B ▲ |
| Q1-2025 | $5.79B ▲ | $78.35B ▲ | $60.73B ▲ | $18.27B ▲ |
| Q4-2024 | $3.71B ▲ | $59.46B ▲ | $46.38B ▲ | $13.67B ▼ |
| Q3-2024 | $3.21B | $58.05B | $44.6B | $14.01B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.71B ▲ | $3.03B ▲ | $-2.15B ▼ | $-1.71B ▲ | $-494.65M ▲ | $2.6B ▲ |
| Q2-2025 | $1.65B ▼ | $2.1B ▲ | $-625M ▲ | $-2.37B ▼ | $-927M ▼ | $1.46B ▲ |
| Q1-2025 | $1.77B ▲ | $1.15B ▼ | $-1.14B ▼ | $858M ▲ | $848M ▲ | $697M ▼ |
| Q4-2024 | $501M ▲ | $2.33B ▲ | $-1.12B ▼ | $-842M ▲ | $375M ▲ | $1.19B ▼ |
| Q3-2024 | $65M | $2.15B | $-731M | $-1.24B | $149M | $1.31B |
CEO
Julie Belita Brown
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-07-22 | Forward | 613:500 |
| 2022-07-19 | Reverse | 4:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 82
Ratings Snapshot
Rating : B+
Price Target
Institutional Ownership
DODGE & COX
Shares:78.4M
Value:$3.98B
FMR LLC
Shares:66.14M
Value:$3.36B
FISHER ASSET MANAGEMENT, LLC
Shares:32.23M
Value:$1.64B
Summary
Showing Top 3 of 1,271